Developing novel complement activation assays for application in basic and clinical research
Studying the cross-talk between complement and TLRs, in particular to the co-receptor CD14
Investigating the effect on inflammation by inhibiting complement activation and CD14 using human whole blood in vitro models and in vivo animal models of human diseases
Studying the “Thromboinflammation” and new complex whole blood models to reveal cross-talk between biological systems ex vivo
Studying complement activation in patients with diseases being tentative candidates for future complement intervention
Develop tools for evaluation of the effect of complement therapy in the clinic
Roos J, Zinngrebe J, Huber-Lang M, Lupu L, Schmidt MA, Strobel H, Westhoff MA, Stifel U, Gebhard F, Wabitsch M, Mollnes TE, Debatin KM, Halbgebauer R, Fischer-Posovszky P(2024) Trauma-associated extracellular histones mediate inflammation via a MYD88-IRAK1-ERK signaling axis and induce lytic cell death in human adipocytes Cell Death Dis, 15(4), 285 DOI 10.1038/s41419-024-06676-9, PubMed 38653969
Soloey-Nilsen H, Nygaard-Odeh K, Kristiansen MG, Kvig EI, Brekke OL, Mollnes TE, Berk M, Reitan SK, Oiesvold T(2023) Transdiagnostic Associations between Anger Hostility and Chemokine Interferon-gamma Inducible Protein 10 Clin Psychopharmacol Neurosci, 22(2), 285-294 DOI 10.9758/cpn.23.1091, PubMed 38627075
Barratt-Due A, Pettersen K, Børresdatter-Dahl T, Holter JC, Grønli RH, Dyrhol-Riise AM, Lerum TV, Holten AR, Tonby K, Trøseid M, Skjønsberg OH, Granerud BK, Heggelund L, Kildal AB, Schjalm C, Aaløkken TM, Aukrust P, Ueland T, Mollnes TE, Halvorsen B, NOR‐Solidarity study groupThe Norwegian SARS‐CoV‐2 study group(2024) Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients J Intern Med(in press) DOI 10.1111/joim.13783, PubMed 38539241